Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNKS | O95271 | 1/20 | 0.44 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 6/20 | 0.38 |
| ▸ | HTR2C | P28335 | 6/20 | 0.38 |
| ▸ | HTR2B | P41595 | 6/20 | 0.38 |
| ▸ | AVPR1A | P37288 | 7/20 | 0.37 |
| ▸ | SPR | P35270 | 1/20 | 0.37 |
| ▸ | HTR6 | P50406 | 1/20 | 0.36 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10218206 | 0.89 | HTR2A (0.50) | TNKSTNKS2HTR2AHTR2CHTR2B | |
| SCHEMBL14700100 | 0.83 | HTR2A (0.38) | HTR2AHTR2CHTR2BHTR6 | |
| SCHEMBL10218531 | 0.81 | HTR2A (0.40) | HTR2AHTR2CHTR2BSPRHTR6 | |
| SCHEMBL10218551 | 0.80 | HTR2A (0.37) | HTR2AHTR2CHTR2BSPRHTR6 | |
| SCHEMBL10218533 | 0.79 | TSHR (0.43) | HTR2AHTR2CHTR2BHTR6 | |
| SCHEMBL10218579 | 0.79 | HTR2A (0.38) | HTR2AHTR2CHTR2BSPRHTR6 | |
| SCHEMBL10218564 | 0.78 | HTR2A (0.54) | HTR2AHTR2CHTR2BSPRHTR6 | |
| SCHEMBL10218562 | 0.77 | HTR2A (0.43) | HTR2AHTR2CHTR2BHTR6 | |
| SCHEMBL10218541 | 0.76 | HTR2A (0.37) | HTR2AHTR2CHTR2BSPRHTR6 | |
| SCHEMBL10218537 | 0.76 | SPR (0.40) | HTR2AHTR2CHTR2BSPRHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9346816-B2 | 6,7,8,9-tetrahydro-5H-1,4,7,10a-tetraaza-cyclohept[f]indene derivatives, pharmaceutical compositions containing these compounds, their use and processes for preparing them | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-05-24 | — | — | US | disclosed |
| US-9346816-B2 | 6,7,8,9-tetrahydro-5H-1,4,7,10a-tetraaza-cyclohept[f]indene derivatives, pharmaceutical compositions containing these compounds, their use and processes for preparing them | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-05-24 | — | — | US | disclosed |
| US-20120165304-A1 | 6,7,8,9-Tetrahydro-5H-1,4,7,10a-tetraaza-cyclohept[f]indene derivatives, pharmaceutical compositions containing these compounds, their use and processes for preparing them | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-28 | — | — | US | disclosed |
| US-20120165304-A1 | 6,7,8,9-Tetrahydro-5H-1,4,7,10a-tetraaza-cyclohept[f]indene derivatives, pharmaceutical compositions containing these compounds, their use and processes for preparing them | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165304-A1 | 6,7,8,9-Tetrahydro-5H-1,4,7,10a-tetraaza-cyclohept[f]indene derivatives, pharmaceutical compositions containing these compounds, their use and processes for preparing them | HTR1A, HTR2C, TPH1 | TNKS 2295/4885TNKS2 2735/4885HTR2A 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.